{"id":41475,"date":"2023-02-12T03:00:19","date_gmt":"2023-02-12T03:00:19","guid":{"rendered":"https:\/\/www.sisinternational.com\/?page_id=41475"},"modified":"2026-05-06T23:09:57","modified_gmt":"2026-05-07T03:09:57","slug":"hearing-loss-market-research","status":"publish","type":"page","link":"https:\/\/www.sisinternational.com\/pl\/ekspertyza\/hearing-loss-market-research\/","title":{"rendered":"Hearing Loss Market Research | SIS International"},"content":{"rendered":"
\n

Badania rynku utraty s\u0142uchu<\/h1>\n
\"SIS<\/figure>\n<\/p>\n

Hearing loss is a decline in auditory perception. It can be brought on by a number of things, such as ear or inner ear damage, loud noise exposure, specific drugs, and aging. Mild to severe hearing loss can be either temporary or permanent. Hearing loss symptoms include trouble understanding words, difficulty hearing in noisy situations, and ringing or buzzing in the ears. Hearing loss can be treated in a number of ways, including surgery, cochlear implants, and hearing aids.<\/p>\n

Benefits of Having a Business that Helps people with Hearing Loss:<\/h2>\n<\/div>\n

Hearing Loss Market Research: How Leading Audiology and Therapeutic Innovators Build Commercial Conviction<\/h1>\n

Hearing loss is shifting from a device-centric category into a therapeutic frontier. Gene therapy candidates, biologics, and next-generation cochlear implants are converging on the same patient population, and the commercial questions are sharper than the science. Who pays. Who decides. Who refers. What parents will accept for an infant.<\/p>\n

Hearing loss market research now sits at the center of these decisions. The firms making confident bets are the ones running structured primary research with parents, audiologists, ENTs, and payers across multiple geographies before the pivotal trial reads out, not after.<\/p>\n

Why Hearing Loss Market Research Has Become a Boardroom Priority<\/h2>\n

The category has expanded beyond hearing aids and implants. Gene therapy programs targeting otoferlin-related deafness, regenerative biologics, and pharmacological otoprotection have created a pipeline that competes for the same diagnostic pathway and the same family decision. Each modality requires a different evidence package and a different payer conversation.<\/p>\n

Parents of newborns flagged through universal hearing screening make decisions inside a 90-day window. That window governs everything: KOL mapping, referral economics, market access strategy, and launch sequencing. Hearing loss market research that ignores the window produces forecasts that overstate adoption and understate the cost of patient identification.<\/p>\n

SIS International’s qualitative work with parents of pediatric hearing loss patients across Spain, the United Kingdom, Mexico, and Latin America consistently surfaces a pattern leadership teams underestimate: families weigh the reversibility and timing of an intervention more heavily than its efficacy ceiling. A treatment positioned as a one-time pediatric procedure faces different acceptance dynamics than one framed as an alternative to cochlear implantation.<\/span><\/p>\n

The Evidence Gaps Conventional Secondary Data Cannot Close<\/h2>\n

Syndicated reports size the hearing aid and cochlear implant markets reasonably well. They cannot answer the questions a VP of Commercial actually needs answered before a launch decision.<\/p>\n

How does an ENT in Madrid sequence the conversation when a newborn fails the otoacoustic emissions test. What does a private insurer in Mexico require to reimburse a novel biologic when cochlear implants are already covered under public schemes. How do parents in the UK NHS pathway interpret “gene therapy” against “cochlear implant” when both are presented as standard of care candidates. Secondary data is silent on each.<\/p>\n

The leading audiology innovators close these gaps with B2B expert interviews among pediatric audiologists, ENT surgeons, geneticists, and payer medical directors, paired with longitudinal parent ethnography. The combination produces a patient journey map that a forecasting model can actually use.<\/p>\n

What the Best Hearing Loss Market Research Programs Get Right<\/h2>\n

Three design choices separate research that drives commercial conviction from research that produces decks.<\/p>\n

Multi-country qualitative before quantitative.<\/strong> Hearing loss pathways differ sharply between public and private systems. A Spanish family navigating Seguridad Social moves through different gatekeepers than a UK family inside the NHS, a Mexican family on private insurance, or a US family on commercial plans. Quantitative instruments fielded before this variation is mapped produce averages that describe no one.<\/p>\n

Expectant parents as a distinct cohort.<\/strong> Families with a known genetic risk make different decisions than families confronting a new diagnosis. Discussion guides that pool both groups dilute the most actionable insight in the category: how prenatal counseling shapes acceptance of postnatal intervention.<\/p>\n

Concept testing under realistic information conditions.<\/strong> Parents will not encounter a clean one-pager at point of decision. They will encounter a conflicted ENT, an audiologist with strong cochlear implant priors, a pediatrician with limited genetics fluency, and family members on social media. Concept tests run under sanitized conditions overstate willingness to adopt.<\/p>\n

Building the Commercial Case Across the Stakeholder Chain<\/h2>\n

Pediatric hearing loss is one of the most multi-stakeholder decisions in medicine. The patient cannot consent. The decision-maker is a parent dyad. The gatekeeper is an audiologist. The prescriber is an ENT or geneticist. The payer is a public scheme, a private insurer, or both in sequence. Each link requires its own evidence.<\/p>\n

In structured interviews SIS International has conducted with parents across Spain, the UK, and Latin American markets, fathers and mothers consistently divide research roles: one parent absorbs the clinical detail, the other absorbs the lived-experience content from other families. Marketing strategies that target a single decision-maker miss half the conversation that actually drives the choice.<\/span><\/p>\n

On the provider side, the installed base of cochlear implant centers shapes referral economics in ways gene therapy entrants frequently misjudge. Surgeons trained on a specific implant platform have switching costs measured in years of clinical confidence, not pricing. Total cost of ownership for the health system, including device, surgery, mapping sessions, and rehabilitation, is the comparator a payer will actually use.<\/p>\n

The SIS Approach to Hearing Loss Market Research<\/h2>\n
\"SIS<\/figure>\n

SIS International has executed hearing loss market<\/a> research across Spain, the UK, Mexico, Argentina, Venezuela, and additional European and Latin American markets, covering parents of newly diagnosed children, expectant parents with known genetic risk, audiologists, ENT surgeons, and payer stakeholders. The work spans device manufacturers, cochlear implant developers, and gene therapy sponsors preparing for first-in-human and pivotal-stage commercial planning.<\/p>\n

The methodology stack includes:<\/p>\n